Aileron Therapeutics Garners $30,000,000 Series E Funding Round

  • Feed Type
  • Date
    11/18/2013
  • Company Name
    Aileron Therapeutics
  • Mailing Address
    281 Albany St. Cambridge, MA 02139
  • Company Description
    Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeuticsfor the treatment of cancer and other diseases.
  • Website
    http://www.aileronrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    In particular, the financing will accelerate Aileron’s proprietary oncology clinical candidate, ALRN-6924, into clinical development in 2014 as a highly potent and specific re-activator of p53, a tumor suppressor protein that represents one of the most important oncology drug targets.
  • M&A Terms
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    SR One
  • Venture Investor
    Excel Venture Management

By posting a comment, you agree to our terms and conditions.